FDA Staff Questions Chiron Transplant Drug

Chiron Corp.’s experimental lung transplant drug Pulminiq failed to show that it reduced acute organ rejection in a small, limited clinical trial, Food and Drug Administration staff reviewers said in documents.

The trial showed that more patients taking the drug lived for two years, but without more data it wasn’t clear if that was a result of the drug, FDA staff said.